 Kennon Heard
Concepts (645)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 39 | 2023 | 256 | 8.610 |
Why?
| | Chemical and Drug Induced Liver Injury | 15 | 2023 | 137 | 4.860 |
Why?
| | Analgesics, Non-Narcotic | 20 | 2022 | 124 | 4.480 |
Why?
| | Drug Overdose | 30 | 2022 | 333 | 4.110 |
Why?
| | Emergency Service, Hospital | 41 | 2023 | 1986 | 3.550 |
Why?
| | Poison Control Centers | 12 | 2024 | 97 | 3.470 |
Why?
| | Poisoning | 17 | 2017 | 118 | 3.100 |
Why?
| | Alanine Transaminase | 14 | 2023 | 151 | 2.670 |
Why?
| | Acetylcysteine | 11 | 2023 | 151 | 2.650 |
Why?
| | Cocaine | 10 | 2011 | 150 | 2.500 |
Why?
| | Cannabis | 9 | 2020 | 438 | 2.450 |
Why?
| | Prescription Drugs | 9 | 2018 | 116 | 2.280 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 921 | 1.620 |
Why?
| | Antidotes | 9 | 2020 | 145 | 1.560 |
Why?
| | Legislation, Drug | 5 | 2017 | 81 | 1.510 |
Why?
| | Cysteine | 4 | 2017 | 192 | 1.400 |
Why?
| | Antipsychotic Agents | 7 | 2019 | 195 | 1.370 |
Why?
| | Marijuana Use | 4 | 2021 | 192 | 1.260 |
Why?
| | Medication Errors | 5 | 2015 | 97 | 1.190 |
Why?
| | Male | 103 | 2022 | 63748 | 1.180 |
Why?
| | Humans | 154 | 2024 | 130305 | 1.130 |
Why?
| | Emergency Medicine | 6 | 2019 | 227 | 1.130 |
Why?
| | Cocaine-Related Disorders | 5 | 2011 | 108 | 1.130 |
Why?
| | Pain | 9 | 2020 | 765 | 1.100 |
Why?
| | Toxicology | 4 | 2021 | 42 | 1.090 |
Why?
| | Drug Packaging | 2 | 2017 | 42 | 1.090 |
Why?
| | Female | 95 | 2022 | 68842 | 1.020 |
Why?
| | Adult | 73 | 2022 | 35711 | 1.010 |
Why?
| | Medication Reconciliation | 2 | 2016 | 29 | 0.990 |
Why?
| | Dose-Response Relationship, Drug | 16 | 2017 | 1983 | 0.970 |
Why?
| | Antidepressive Agents, Tricyclic | 5 | 2014 | 30 | 0.920 |
Why?
| | Spider Bites | 5 | 2019 | 9 | 0.910 |
Why?
| | Diphenhydramine | 4 | 2023 | 31 | 0.900 |
Why?
| | Akathisia, Drug-Induced | 2 | 2020 | 6 | 0.890 |
Why?
| | Antivenins | 5 | 2019 | 59 | 0.880 |
Why?
| | Thiazoles | 4 | 2009 | 117 | 0.870 |
Why?
| | Benzodiazepines | 6 | 2023 | 133 | 0.860 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2023 | 14 | 0.850 |
Why?
| | Spider Venoms | 4 | 2019 | 11 | 0.850 |
Why?
| | Heart Arrest | 8 | 2018 | 328 | 0.820 |
Why?
| | Muscarinic Antagonists | 3 | 2023 | 27 | 0.820 |
Why?
| | Middle Aged | 54 | 2022 | 31322 | 0.820 |
Why?
| | Lorazepam | 3 | 2023 | 26 | 0.810 |
Why?
| | Young Adult | 30 | 2020 | 12404 | 0.810 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 206 | 0.790 |
Why?
| | Seizures | 6 | 2011 | 396 | 0.780 |
Why?
| | Referral and Consultation | 2 | 2020 | 736 | 0.770 |
Why?
| | Physostigmine | 2 | 2020 | 11 | 0.760 |
Why?
| | Emergency Treatment | 4 | 2015 | 116 | 0.760 |
Why?
| | Piperazines | 4 | 2009 | 334 | 0.760 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 345 | 0.750 |
Why?
| | Black Widow Spider | 4 | 2019 | 9 | 0.750 |
Why?
| | Medical History Taking | 3 | 2018 | 119 | 0.740 |
Why?
| | Delirium | 2 | 2020 | 78 | 0.740 |
Why?
| | Dopamine Uptake Inhibitors | 3 | 2011 | 55 | 0.740 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2014 | 113 | 0.700 |
Why?
| | Abdominal Pain | 2 | 2019 | 149 | 0.700 |
Why?
| | Suicide, Attempted | 5 | 2012 | 357 | 0.690 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 518 | 0.670 |
Why?
| | Vasoconstrictor Agents | 4 | 2009 | 131 | 0.670 |
Why?
| | Back Pain | 1 | 2020 | 52 | 0.670 |
Why?
| | Retrospective Studies | 31 | 2023 | 14675 | 0.670 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 82 | 0.660 |
Why?
| | Patient Handoff | 1 | 2020 | 31 | 0.660 |
Why?
| | Buprenorphine | 2 | 2020 | 171 | 0.640 |
Why?
| | Ketorolac | 1 | 2019 | 18 | 0.640 |
Why?
| | Haloperidol | 1 | 2019 | 36 | 0.640 |
Why?
| | Social Work | 1 | 2020 | 84 | 0.620 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 21 | 0.620 |
Why?
| | Tertiary Care Centers | 3 | 2017 | 147 | 0.600 |
Why?
| | Gastric Lavage | 3 | 2009 | 9 | 0.600 |
Why?
| | Vomiting | 6 | 2019 | 129 | 0.590 |
Why?
| | Prospective Studies | 18 | 2023 | 7131 | 0.590 |
Why?
| | Colorado | 15 | 2021 | 4471 | 0.590 |
Why?
| | Substance-Related Disorders | 5 | 2012 | 1023 | 0.590 |
Why?
| | Immunoglobulin Fab Fragments | 4 | 2019 | 78 | 0.580 |
Why?
| | Hypotension | 2 | 2022 | 118 | 0.580 |
Why?
| | Drug Storage | 2 | 2017 | 58 | 0.570 |
Why?
| | Child | 28 | 2023 | 20961 | 0.570 |
Why?
| | Cannabinoids | 3 | 2017 | 132 | 0.560 |
Why?
| | Electronic Health Records | 4 | 2024 | 979 | 0.560 |
Why?
| | Accidents, Home | 1 | 2017 | 29 | 0.560 |
Why?
| | Medical Marijuana | 2 | 2019 | 108 | 0.550 |
Why?
| | Pulmonary Embolism | 3 | 2021 | 211 | 0.540 |
Why?
| | Plant Preparations | 2 | 2015 | 31 | 0.540 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2007 | 83 | 0.540 |
Why?
| | Calcium Gluconate | 1 | 2016 | 4 | 0.540 |
Why?
| | Hypocalcemia | 1 | 2016 | 28 | 0.530 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2016 | 52 | 0.520 |
Why?
| | Health Records, Personal | 1 | 2016 | 25 | 0.520 |
Why?
| | Mobile Applications | 1 | 2018 | 159 | 0.510 |
Why?
| | Nonprescription Drugs | 4 | 2016 | 69 | 0.510 |
Why?
| | Blood Proteins | 1 | 2017 | 239 | 0.500 |
Why?
| | Emergency Medical Services | 4 | 2016 | 564 | 0.500 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1294 | 0.500 |
Why?
| | Antidepressive Agents | 2 | 2012 | 228 | 0.490 |
Why?
| | Fat Emulsions, Intravenous | 2 | 2014 | 29 | 0.490 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 260 | 0.490 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 42 | 0.480 |
Why?
| | Liver | 6 | 2022 | 1846 | 0.480 |
Why?
| | Treatment Outcome | 18 | 2020 | 10341 | 0.480 |
Why?
| | Electrocardiography | 5 | 2013 | 615 | 0.470 |
Why?
| | Child, Preschool | 13 | 2018 | 10514 | 0.460 |
Why?
| | Infant | 12 | 2018 | 9049 | 0.460 |
Why?
| | Asymptomatic Diseases | 2 | 2013 | 86 | 0.450 |
Why?
| | Crime | 2 | 2011 | 57 | 0.440 |
Why?
| | Observer Variation | 3 | 2010 | 324 | 0.440 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 27 | 0.430 |
Why?
| | Energy Drinks | 1 | 2013 | 4 | 0.430 |
Why?
| | Adolescent | 27 | 2020 | 20374 | 0.430 |
Why?
| | Performance-Enhancing Substances | 1 | 2013 | 9 | 0.430 |
Why?
| | Arrhythmias, Cardiac | 3 | 2022 | 318 | 0.420 |
Why?
| | Accidents | 1 | 2013 | 41 | 0.420 |
Why?
| | Double-Blind Method | 7 | 2020 | 1878 | 0.420 |
Why?
| | Bradycardia | 1 | 2013 | 56 | 0.420 |
Why?
| | Plasmapheresis | 1 | 2013 | 25 | 0.420 |
Why?
| | Diet Surveys | 1 | 2013 | 93 | 0.420 |
Why?
| | Amphotericin B | 1 | 2013 | 29 | 0.420 |
Why?
| | Poisons | 2 | 2023 | 23 | 0.420 |
Why?
| | Hematemesis | 1 | 2012 | 3 | 0.410 |
Why?
| | beta-Alanine | 1 | 2012 | 17 | 0.410 |
Why?
| | Phytotherapy | 1 | 2013 | 76 | 0.410 |
Why?
| | Aspartate Aminotransferases | 3 | 2010 | 86 | 0.410 |
Why?
| | Stomach Diseases | 1 | 2012 | 20 | 0.410 |
Why?
| | Foreign Bodies | 2 | 2011 | 104 | 0.410 |
Why?
| | Ethers | 1 | 2012 | 16 | 0.410 |
Why?
| | Sulfonylurea Compounds | 2 | 2010 | 47 | 0.400 |
Why?
| | Dronabinol | 4 | 2021 | 167 | 0.400 |
Why?
| | Antithrombins | 1 | 2012 | 56 | 0.400 |
Why?
| | Citalopram | 1 | 2012 | 34 | 0.400 |
Why?
| | Aged | 27 | 2019 | 22282 | 0.390 |
Why?
| | Liver Function Tests | 7 | 2020 | 110 | 0.390 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 766 | 0.390 |
Why?
| | Antifungal Agents | 1 | 2013 | 132 | 0.390 |
Why?
| | Propafenone | 1 | 2011 | 2 | 0.390 |
Why?
| | Thiophenes | 1 | 2012 | 119 | 0.380 |
Why?
| | Alcohol Drinking | 4 | 2012 | 746 | 0.380 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2282 | 0.380 |
Why?
| | Disease Models, Animal | 9 | 2011 | 4044 | 0.380 |
Why?
| | C-Peptide | 2 | 2010 | 163 | 0.380 |
Why?
| | Firesetting Behavior | 1 | 2011 | 1 | 0.380 |
Why?
| | Infusions, Intravenous | 6 | 2013 | 395 | 0.380 |
Why?
| | Clinical Enzyme Tests | 2 | 2013 | 11 | 0.370 |
Why?
| | Charcoal | 4 | 2006 | 24 | 0.370 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 506 | 0.370 |
Why?
| | Benzimidazoles | 1 | 2012 | 160 | 0.370 |
Why?
| | Temperance | 2 | 2010 | 13 | 0.370 |
Why?
| | Administration, Intravenous | 4 | 2016 | 140 | 0.370 |
Why?
| | Burns | 2 | 2015 | 289 | 0.370 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 11 | 0.360 |
Why?
| | Aged, 80 and over | 15 | 2018 | 7128 | 0.360 |
Why?
| | Brain Edema | 1 | 2011 | 61 | 0.360 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3069 | 0.360 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 29 | 0.360 |
Why?
| | Amitriptyline | 2 | 2001 | 21 | 0.360 |
Why?
| | Blood Chemical Analysis | 3 | 2021 | 96 | 0.360 |
Why?
| | Self-Injurious Behavior | 1 | 2012 | 122 | 0.350 |
Why?
| | Evidence-Based Medicine | 4 | 2023 | 733 | 0.350 |
Why?
| | Immunologic Factors | 2 | 2019 | 232 | 0.350 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 170 | 0.350 |
Why?
| | Population Surveillance | 1 | 2013 | 429 | 0.340 |
Why?
| | Hydrofluoric Acid | 2 | 2016 | 8 | 0.340 |
Why?
| | Liver Failure | 1 | 2011 | 93 | 0.340 |
Why?
| | Anaphylaxis | 2 | 2012 | 161 | 0.340 |
Why?
| | Pharmaceutical Vehicles | 1 | 2010 | 11 | 0.340 |
Why?
| | Time Factors | 12 | 2020 | 6615 | 0.340 |
Why?
| | Propylene Glycol | 1 | 2010 | 10 | 0.340 |
Why?
| | Barium | 1 | 2009 | 27 | 0.340 |
Why?
| | Explosive Agents | 1 | 2009 | 8 | 0.330 |
Why?
| | Hypokalemia | 1 | 2009 | 25 | 0.330 |
Why?
| | Imines | 2 | 2022 | 8 | 0.330 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2007 | 89 | 0.330 |
Why?
| | Warfarin | 1 | 2010 | 151 | 0.330 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 45 | 0.330 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 58 | 0.330 |
Why?
| | Cross-Sectional Studies | 9 | 2020 | 5083 | 0.330 |
Why?
| | Emetics | 2 | 2006 | 7 | 0.320 |
Why?
| | Deception | 1 | 2009 | 18 | 0.320 |
Why?
| | Random Allocation | 3 | 2007 | 353 | 0.320 |
Why?
| | United States | 17 | 2023 | 14110 | 0.320 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 5400 | 0.320 |
Why?
| | Benzoquinones | 2 | 2022 | 47 | 0.320 |
Why?
| | Risk Factors | 9 | 2017 | 9865 | 0.310 |
Why?
| | Oximetry | 1 | 2009 | 86 | 0.310 |
Why?
| | Risk Assessment | 8 | 2017 | 3310 | 0.310 |
Why?
| | Fluorides | 2 | 2016 | 49 | 0.310 |
Why?
| | Odds Ratio | 7 | 2017 | 1027 | 0.310 |
Why?
| | Length of Stay | 3 | 2020 | 1135 | 0.310 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 74 | 0.310 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 150 | 0.300 |
Why?
| | Cyanoacrylates | 1 | 2008 | 4 | 0.300 |
Why?
| | Eyelashes | 1 | 2008 | 4 | 0.300 |
Why?
| | Adhesives | 1 | 2008 | 13 | 0.290 |
Why?
| | Hypoglycemia | 2 | 2010 | 428 | 0.290 |
Why?
| | Intellectual Disability | 1 | 2009 | 153 | 0.290 |
Why?
| | Animals | 22 | 2019 | 35076 | 0.290 |
Why?
| | Detergents | 1 | 2008 | 45 | 0.290 |
Why?
| | Reference Values | 4 | 2017 | 793 | 0.290 |
Why?
| | Alcoholism | 4 | 2023 | 764 | 0.290 |
Why?
| | Cardiovascular System | 1 | 2009 | 139 | 0.280 |
Why?
| | Brugada Syndrome | 1 | 2007 | 9 | 0.280 |
Why?
| | Publishing | 1 | 2009 | 141 | 0.280 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 86 | 0.280 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 601 | 0.280 |
Why?
| | Diazepam | 1 | 2007 | 26 | 0.280 |
Why?
| | Niacin | 1 | 2007 | 19 | 0.280 |
Why?
| | Mice, Inbred Strains | 4 | 2009 | 408 | 0.270 |
Why?
| | Vitamin B Complex | 1 | 2007 | 41 | 0.270 |
Why?
| | Specimen Handling | 1 | 2008 | 166 | 0.270 |
Why?
| | Pediatrics | 1 | 2015 | 1063 | 0.270 |
Why?
| | Thromboembolism | 1 | 2007 | 106 | 0.270 |
Why?
| | Analgesics | 4 | 2017 | 165 | 0.270 |
Why?
| | Brain Infarction | 1 | 2006 | 22 | 0.270 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 31 | 0.260 |
Why?
| | Decontamination | 1 | 2006 | 26 | 0.250 |
Why?
| | Anticoagulants | 1 | 2010 | 627 | 0.250 |
Why?
| | Nausea | 4 | 2014 | 109 | 0.250 |
Why?
| | Amiodarone | 1 | 2005 | 25 | 0.250 |
Why?
| | Self Report | 4 | 2021 | 802 | 0.250 |
Why?
| | Venous Thrombosis | 1 | 2007 | 161 | 0.250 |
Why?
| | Intention | 1 | 2007 | 159 | 0.250 |
Why?
| | Age Factors | 7 | 2017 | 3153 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2012 | 1381 | 0.250 |
Why?
| | Epilepsy | 2 | 2020 | 319 | 0.250 |
Why?
| | Vasospasm, Intracranial | 1 | 2005 | 17 | 0.250 |
Why?
| | Eating | 4 | 2017 | 368 | 0.250 |
Why?
| | Sodium Nitrite | 1 | 2005 | 39 | 0.240 |
Why?
| | Databases, Factual | 1 | 2010 | 1300 | 0.240 |
Why?
| | Drug Utilization | 5 | 2014 | 170 | 0.240 |
Why?
| | Education, Medical | 2 | 2021 | 241 | 0.240 |
Why?
| | Calcium | 3 | 2016 | 1189 | 0.240 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2005 | 62 | 0.240 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 790 | 0.230 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 333 | 0.230 |
Why?
| | Coma | 2 | 2006 | 32 | 0.230 |
Why?
| | Biomarkers | 7 | 2021 | 3923 | 0.230 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1218 | 0.220 |
Why?
| | Hospitals, Urban | 5 | 2021 | 134 | 0.220 |
Why?
| | Injections, Intraperitoneal | 4 | 2009 | 106 | 0.220 |
Why?
| | Case-Control Studies | 4 | 2022 | 3369 | 0.220 |
Why?
| | Anti-Anxiety Agents | 2 | 2020 | 44 | 0.220 |
Why?
| | Insulin | 3 | 2019 | 2322 | 0.210 |
Why?
| | Animal Experimentation | 1 | 2003 | 6 | 0.210 |
Why?
| | Glasgow Coma Scale | 1 | 2004 | 170 | 0.210 |
Why?
| | Sensitivity and Specificity | 5 | 2010 | 1854 | 0.210 |
Why?
| | Calcium Chloride | 1 | 2003 | 14 | 0.210 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 264 | 0.210 |
Why?
| | Hospitals, Teaching | 3 | 2014 | 112 | 0.210 |
Why?
| | Magnesium Sulfate | 1 | 2003 | 17 | 0.210 |
Why?
| | Longevity | 3 | 2009 | 151 | 0.200 |
Why?
| | Documentation | 1 | 2024 | 184 | 0.200 |
Why?
| | Umbilical Cord | 2 | 2021 | 84 | 0.200 |
Why?
| | Placebos | 2 | 2014 | 204 | 0.200 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 260 | 0.190 |
Why?
| | Desipramine | 1 | 2001 | 10 | 0.190 |
Why?
| | Phenylurea Compounds | 1 | 2022 | 89 | 0.190 |
Why?
| | Logistic Models | 3 | 2017 | 1980 | 0.190 |
Why?
| | Confidence Intervals | 4 | 2010 | 318 | 0.190 |
Why?
| | Opiate Substitution Treatment | 2 | 2020 | 142 | 0.190 |
Why?
| | Research Design | 3 | 2006 | 1052 | 0.190 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 173 | 0.190 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 163 | 0.190 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 109 | 0.180 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2785 | 0.180 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 21 | 0.180 |
Why?
| | Heart Atria | 1 | 2001 | 130 | 0.180 |
Why?
| | Fractures, Bone | 2 | 2017 | 418 | 0.180 |
Why?
| | Acute Disease | 2 | 2019 | 981 | 0.180 |
Why?
| | Myocardial Contraction | 1 | 2001 | 337 | 0.170 |
Why?
| | Immunoglobulin Fragments | 1 | 1999 | 16 | 0.170 |
Why?
| | Lysergic Acid Diethylamide | 1 | 1999 | 2 | 0.170 |
Why?
| | Droperidol | 1 | 1999 | 5 | 0.170 |
Why?
| | Lithium Carbonate | 1 | 1999 | 6 | 0.170 |
Why?
| | Wisconsin | 1 | 2020 | 102 | 0.170 |
Why?
| | Serotonin Syndrome | 1 | 1999 | 5 | 0.170 |
Why?
| | Survival Analysis | 4 | 2010 | 1293 | 0.160 |
Why?
| | Starch | 1 | 2019 | 22 | 0.160 |
Why?
| | Serotonin Receptor Agonists | 1 | 1999 | 27 | 0.160 |
Why?
| | Scorpion Stings | 1 | 1999 | 1 | 0.160 |
Why?
| | Nutritive Value | 1 | 2019 | 36 | 0.160 |
Why?
| | Community Health Workers | 1 | 2020 | 50 | 0.160 |
Why?
| | Geriatric Assessment | 2 | 2011 | 203 | 0.160 |
Why?
| | Ventricular Premature Complexes | 1 | 1999 | 35 | 0.160 |
Why?
| | Healthy Volunteers | 2 | 2019 | 204 | 0.160 |
Why?
| | Mass Screening | 1 | 2007 | 1139 | 0.160 |
Why?
| | Administration, Oral | 4 | 2019 | 788 | 0.160 |
Why?
| | Thrombocytopenia | 1 | 2021 | 188 | 0.160 |
Why?
| | Immune System | 1 | 2020 | 176 | 0.160 |
Why?
| | Metabolome | 1 | 2022 | 320 | 0.160 |
Why?
| | Fallopian Tube Diseases | 1 | 1998 | 5 | 0.160 |
Why?
| | Pregnancy, Tubal | 1 | 1998 | 5 | 0.160 |
Why?
| | Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.150 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 1998 | 21 | 0.150 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 152 | 0.150 |
Why?
| | Cannabidiol | 1 | 2020 | 90 | 0.150 |
Why?
| | Snake Bites | 1 | 1999 | 56 | 0.150 |
Why?
| | Cohort Studies | 7 | 2023 | 5431 | 0.150 |
Why?
| | Plant Extracts | 1 | 2020 | 180 | 0.150 |
Why?
| | Drug Therapy, Combination | 4 | 2011 | 1028 | 0.150 |
Why?
| | Anticonvulsants | 1 | 2020 | 200 | 0.150 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 517 | 0.150 |
Why?
| | Sex Factors | 5 | 2022 | 1965 | 0.150 |
Why?
| | Sulfasalazine | 1 | 1998 | 23 | 0.150 |
Why?
| | Drug Antagonism | 2 | 2009 | 10 | 0.150 |
Why?
| | Faculty, Medical | 1 | 2021 | 265 | 0.140 |
Why?
| | Dyspnea | 1 | 1999 | 236 | 0.140 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2018 | 86 | 0.140 |
Why?
| | Dietary Fats | 1 | 2019 | 303 | 0.140 |
Why?
| | Drug Interactions | 4 | 2014 | 370 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 274 | 0.140 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1341 | 0.140 |
Why?
| | Gastrointestinal Agents | 1 | 1998 | 62 | 0.140 |
Why?
| | Mice | 8 | 2009 | 16832 | 0.140 |
Why?
| | Methotrexate | 1 | 1998 | 250 | 0.140 |
Why?
| | Simulation Training | 1 | 2018 | 82 | 0.140 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 280 | 0.140 |
Why?
| | Survival Rate | 3 | 2013 | 1904 | 0.140 |
Why?
| | Peptide Fragments | 1 | 2021 | 698 | 0.140 |
Why?
| | Incidence | 4 | 2013 | 2657 | 0.140 |
Why?
| | Hypnotics and Sedatives | 1 | 1998 | 159 | 0.140 |
Why?
| | Ammonium Compounds | 1 | 2016 | 3 | 0.130 |
Why?
| | Energy Intake | 1 | 2019 | 454 | 0.130 |
Why?
| | Pain Management | 2 | 2017 | 322 | 0.130 |
Why?
| | Prenatal Care | 1 | 2019 | 273 | 0.130 |
Why?
| | Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 2 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1015 | 0.130 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 108 | 0.130 |
Why?
| | Half-Life | 2 | 2019 | 152 | 0.130 |
Why?
| | Ventricular Fibrillation | 1 | 2016 | 58 | 0.130 |
Why?
| | Pharmacovigilance | 1 | 2015 | 22 | 0.130 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 1974 | 0.130 |
Why?
| | Milk | 1 | 2016 | 129 | 0.120 |
Why?
| | Herniorrhaphy | 1 | 2016 | 60 | 0.120 |
Why?
| | Pilot Projects | 1 | 2020 | 1565 | 0.120 |
Why?
| | Genetic Variation | 1 | 2020 | 939 | 0.120 |
Why?
| | Fatal Outcome | 2 | 2013 | 302 | 0.120 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 74 | 0.120 |
Why?
| | Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.120 |
Why?
| | Models, Biological | 2 | 2015 | 1716 | 0.120 |
Why?
| | Child Behavior | 1 | 2017 | 236 | 0.120 |
Why?
| | Ondansetron | 1 | 2014 | 15 | 0.120 |
Why?
| | Liver Failure, Acute | 1 | 2015 | 63 | 0.120 |
Why?
| | Patient Simulation | 1 | 2014 | 34 | 0.120 |
Why?
| | Hydrocodone | 1 | 2014 | 17 | 0.120 |
Why?
| | Total Quality Management | 1 | 1994 | 61 | 0.120 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2014 | 29 | 0.120 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 90 | 0.110 |
Why?
| | Internship and Residency | 2 | 2014 | 1060 | 0.110 |
Why?
| | Transaminases | 1 | 2014 | 23 | 0.110 |
Why?
| | Curriculum | 1 | 2021 | 929 | 0.110 |
Why?
| | Oxycodone | 1 | 2014 | 49 | 0.110 |
Why?
| | Guanfacine | 1 | 2013 | 3 | 0.110 |
Why?
| | Physicians | 2 | 2020 | 865 | 0.110 |
Why?
| | Remote Consultation | 1 | 2014 | 46 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 2019 | 489 | 0.110 |
Why?
| | Prognosis | 3 | 2011 | 3830 | 0.110 |
Why?
| | Clonidine | 1 | 2013 | 27 | 0.110 |
Why?
| | Vitamins | 1 | 2015 | 175 | 0.110 |
Why?
| | Acute Pain | 1 | 2014 | 46 | 0.110 |
Why?
| | International Normalized Ratio | 2 | 2011 | 47 | 0.110 |
Why?
| | Cesium | 1 | 2013 | 18 | 0.110 |
Why?
| | Indazoles | 1 | 2014 | 67 | 0.110 |
Why?
| | Food | 1 | 2015 | 170 | 0.110 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 15 | 0.100 |
Why?
| | Walking | 1 | 2017 | 502 | 0.100 |
Why?
| | Lethargy | 1 | 2012 | 4 | 0.100 |
Why?
| | Duloxetine Hydrochloride | 1 | 2012 | 12 | 0.100 |
Why?
| | Pain Measurement | 4 | 2019 | 491 | 0.100 |
Why?
| | Dabigatran | 1 | 2012 | 22 | 0.100 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1095 | 0.100 |
Why?
| | Sleep Stages | 1 | 2012 | 44 | 0.100 |
Why?
| | Tachycardia | 1 | 2012 | 56 | 0.100 |
Why?
| | Pyrazoles | 1 | 2016 | 406 | 0.100 |
Why?
| | Chlorides | 1 | 2013 | 138 | 0.100 |
Why?
| | Mycoses | 1 | 2013 | 70 | 0.100 |
Why?
| | Sulfhydryl Reagents | 1 | 2012 | 12 | 0.100 |
Why?
| | Marijuana Abuse | 1 | 2015 | 230 | 0.100 |
Why?
| | Data Collection | 2 | 2013 | 654 | 0.100 |
Why?
| | Dizziness | 1 | 2012 | 80 | 0.100 |
Why?
| | Athletic Performance | 1 | 2013 | 77 | 0.100 |
Why?
| | Sampling Studies | 1 | 2012 | 96 | 0.100 |
Why?
| | Magnesium | 2 | 2004 | 151 | 0.100 |
Why?
| | Arsenicals | 1 | 2012 | 28 | 0.100 |
Why?
| | Accidental Falls | 2 | 2011 | 171 | 0.100 |
Why?
| | Patient Discharge | 2 | 2016 | 866 | 0.100 |
Why?
| | Drug Combinations | 1 | 2013 | 328 | 0.090 |
Why?
| | Information Systems | 1 | 2011 | 63 | 0.090 |
Why?
| | Sulfides | 1 | 2012 | 94 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2010 | 4961 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 240 | 0.090 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.090 |
Why?
| | Laparoscopy | 1 | 2016 | 456 | 0.090 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 19 | 0.090 |
Why?
| | Levamisole | 1 | 2011 | 19 | 0.090 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 541 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2013 | 199 | 0.090 |
Why?
| | Drug Contamination | 1 | 2011 | 53 | 0.090 |
Why?
| | Molecular Structure | 1 | 2012 | 472 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2015 | 534 | 0.090 |
Why?
| | Universities | 1 | 2013 | 406 | 0.090 |
Why?
| | Pharmacogenetics | 1 | 2012 | 171 | 0.090 |
Why?
| | Glipizide | 1 | 2010 | 6 | 0.090 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 14 | 0.090 |
Why?
| | Sports | 1 | 2013 | 226 | 0.090 |
Why?
| | Hepatitis, Alcoholic | 1 | 2010 | 13 | 0.090 |
Why?
| | Troponin | 1 | 2010 | 50 | 0.090 |
Why?
| | Glyburide | 1 | 2010 | 35 | 0.080 |
Why?
| | Crowding | 1 | 2010 | 36 | 0.080 |
Why?
| | Biological Availability | 2 | 2019 | 131 | 0.080 |
Why?
| | Drug Prescriptions | 2 | 2016 | 255 | 0.080 |
Why?
| | Watchful Waiting | 1 | 2010 | 67 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 220 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 938 | 0.080 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 22 | 0.080 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 17 | 0.080 |
Why?
| | Aripiprazole | 1 | 2009 | 16 | 0.080 |
Why?
| | Risperidone | 1 | 2009 | 28 | 0.080 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 191 | 0.080 |
Why?
| | Potassium | 1 | 2009 | 140 | 0.080 |
Why?
| | Dogs | 1 | 2010 | 377 | 0.080 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 131 | 0.080 |
Why?
| | Role | 1 | 2009 | 32 | 0.080 |
Why?
| | Head Protective Devices | 1 | 2009 | 17 | 0.080 |
Why?
| | Quality Control | 1 | 2009 | 155 | 0.080 |
Why?
| | Acidosis | 2 | 2006 | 89 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2013 | 425 | 0.080 |
Why?
| | Glutathione | 3 | 2022 | 340 | 0.080 |
Why?
| | Body Temperature | 1 | 2009 | 216 | 0.080 |
Why?
| | Verapamil | 2 | 2014 | 38 | 0.080 |
Why?
| | Bibliometrics | 1 | 2009 | 54 | 0.080 |
Why?
| | Diarrhea | 1 | 2009 | 179 | 0.080 |
Why?
| | Workload | 1 | 2010 | 154 | 0.080 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 301 | 0.080 |
Why?
| | Skiing | 1 | 2009 | 45 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2015 | 902 | 0.070 |
Why?
| | Bacitracin | 1 | 2008 | 6 | 0.070 |
Why?
| | Adhesiveness | 1 | 2008 | 19 | 0.070 |
Why?
| | Informed Consent | 2 | 2006 | 181 | 0.070 |
Why?
| | Acetone | 1 | 2008 | 12 | 0.070 |
Why?
| | Hair Preparations | 1 | 2008 | 7 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 96 | 0.070 |
Why?
| | Cause of Death | 1 | 2010 | 397 | 0.070 |
Why?
| | Propylene Glycols | 1 | 2008 | 26 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 69 | 0.070 |
Why?
| | Nylons | 1 | 2008 | 20 | 0.070 |
Why?
| | Military Personnel | 1 | 2014 | 521 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 526 | 0.070 |
Why?
| | Students | 1 | 2013 | 584 | 0.070 |
Why?
| | Glycerol | 1 | 2008 | 87 | 0.070 |
Why?
| | Cellulose | 1 | 2008 | 61 | 0.070 |
Why?
| | Substance Abuse Detection | 2 | 2021 | 75 | 0.070 |
Why?
| | Quinolones | 1 | 2009 | 123 | 0.070 |
Why?
| | Drug Synergism | 1 | 2008 | 361 | 0.070 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2007 | 16 | 0.070 |
Why?
| | Laboratories | 1 | 2008 | 104 | 0.070 |
Why?
| | Polypharmacy | 1 | 2008 | 83 | 0.070 |
Why?
| | Tissue Distribution | 2 | 2019 | 297 | 0.070 |
Why?
| | Research | 2 | 2011 | 415 | 0.070 |
Why?
| | Phosphates | 1 | 2008 | 169 | 0.070 |
Why?
| | Formates | 1 | 2006 | 13 | 0.070 |
Why?
| | Defibrillators | 1 | 2006 | 17 | 0.070 |
Why?
| | Methanol | 1 | 2006 | 33 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1219 | 0.070 |
Why?
| | Periodicals as Topic | 1 | 2009 | 209 | 0.070 |
Why?
| | Blindness | 1 | 2006 | 38 | 0.070 |
Why?
| | Hospitalization | 2 | 2011 | 2094 | 0.070 |
Why?
| | Vasopressins | 1 | 2006 | 64 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 427 | 0.070 |
Why?
| | Probability | 2 | 2010 | 314 | 0.060 |
Why?
| | Health Services for the Aged | 1 | 2006 | 72 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 673 | 0.060 |
Why?
| | Spinal Diseases | 1 | 2006 | 48 | 0.060 |
Why?
| | Naproxen | 1 | 2006 | 15 | 0.060 |
Why?
| | Ipecac | 1 | 2005 | 8 | 0.060 |
Why?
| | Aging | 2 | 2014 | 1785 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2009 | 319 | 0.060 |
Why?
| | Population Dynamics | 1 | 2006 | 135 | 0.060 |
Why?
| | Telemedicine | 1 | 2014 | 791 | 0.060 |
Why?
| | Ibuprofen | 1 | 2006 | 80 | 0.060 |
Why?
| | Hospitals, University | 1 | 2006 | 177 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 57 | 0.060 |
Why?
| | Geriatrics | 1 | 2006 | 80 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 40 | 0.060 |
Why?
| | Respiration, Artificial | 1 | 2009 | 600 | 0.060 |
Why?
| | Epinephrine | 1 | 2006 | 180 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1537 | 0.060 |
Why?
| | Risk | 1 | 2007 | 873 | 0.060 |
Why?
| | Spine | 1 | 2006 | 158 | 0.060 |
Why?
| | Single-Blind Method | 1 | 2005 | 274 | 0.060 |
Why?
| | Water | 1 | 2008 | 444 | 0.060 |
Why?
| | Motivation | 1 | 2009 | 544 | 0.060 |
Why?
| | Fluoride Poisoning | 1 | 2004 | 4 | 0.060 |
Why?
| | Blood Glucose | 2 | 2019 | 2100 | 0.060 |
Why?
| | Phenobarbital | 1 | 2023 | 19 | 0.060 |
Why?
| | Resuscitation | 1 | 2006 | 244 | 0.060 |
Why?
| | Guidelines as Topic | 1 | 2005 | 262 | 0.050 |
Why?
| | Maltose | 1 | 2023 | 6 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2023 | 3 | 0.050 |
Why?
| | Health Policy | 1 | 2006 | 361 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 100 | 0.050 |
Why?
| | Sheep | 1 | 2006 | 833 | 0.050 |
Why?
| | Urea | 1 | 2023 | 76 | 0.050 |
Why?
| | Survival | 1 | 2003 | 39 | 0.050 |
Why?
| | Pregnancy | 3 | 2021 | 6301 | 0.050 |
Why?
| | Internet | 1 | 2007 | 618 | 0.050 |
Why?
| | Patient Participation | 1 | 2006 | 406 | 0.050 |
Why?
| | Aspirin | 1 | 2006 | 383 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 83 | 0.050 |
Why?
| | Canada | 1 | 2023 | 356 | 0.050 |
Why?
| | Urban Population | 2 | 2019 | 439 | 0.050 |
Why?
| | Sex Distribution | 2 | 2015 | 361 | 0.050 |
Why?
| | Prevalence | 3 | 2015 | 2576 | 0.050 |
Why?
| | Culture Techniques | 1 | 2001 | 82 | 0.050 |
Why?
| | Blood Physiological Phenomena | 1 | 2021 | 13 | 0.050 |
Why?
| | Neural Conduction | 1 | 2001 | 82 | 0.050 |
Why?
| | Academic Medical Centers | 2 | 2016 | 476 | 0.050 |
Why?
| | Hirudins | 1 | 2021 | 52 | 0.050 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 125 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2139 | 0.050 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2020 | 27 | 0.040 |
Why?
| | Infusions, Parenteral | 1 | 2020 | 39 | 0.040 |
Why?
| | Certification | 1 | 2020 | 95 | 0.040 |
Why?
| | Pirenzepine | 1 | 1999 | 7 | 0.040 |
Why?
| | Scorpions | 1 | 1999 | 2 | 0.040 |
Why?
| | South America | 1 | 1999 | 56 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 708 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 511 | 0.040 |
Why?
| | Blood Cell Count | 2 | 2013 | 54 | 0.040 |
Why?
| | Temperature | 1 | 2022 | 636 | 0.040 |
Why?
| | Narcotics | 1 | 1999 | 48 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 1998 | 20 | 0.040 |
Why?
| | Postprandial Period | 1 | 2019 | 103 | 0.040 |
Why?
| | Manikins | 1 | 2018 | 23 | 0.040 |
Why?
| | Central Nervous System Depressants | 1 | 1999 | 84 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 34 | 0.040 |
Why?
| | Sorption Detoxification | 1 | 1998 | 3 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2001 | 1291 | 0.040 |
Why?
| | Cholinesterase Inhibitors | 1 | 1998 | 28 | 0.040 |
Why?
| | North America | 1 | 1999 | 290 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2019 | 132 | 0.040 |
Why?
| | Lipids | 1 | 2022 | 627 | 0.040 |
Why?
| | Laparotomy | 1 | 1998 | 109 | 0.040 |
Why?
| | Feedback | 1 | 2018 | 160 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1314 | 0.040 |
Why?
| | Cardiomyopathies | 1 | 2001 | 336 | 0.040 |
Why?
| | Central Nervous System | 1 | 1999 | 257 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 95 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 521 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2001 | 845 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 525 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2015 | 1200 | 0.030 |
Why?
| | Bipolar Disorder | 1 | 1999 | 235 | 0.030 |
Why?
| | Registries | 2 | 2010 | 1934 | 0.030 |
Why?
| | Hallucinogens | 1 | 2017 | 87 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1018 | 0.030 |
Why?
| | Dialysis | 1 | 2015 | 18 | 0.030 |
Why?
| | Centrifugation | 1 | 2015 | 29 | 0.030 |
Why?
| | Tennessee | 1 | 1994 | 43 | 0.030 |
Why?
| | Observation | 1 | 2014 | 52 | 0.030 |
Why?
| | Hematocrit | 1 | 1994 | 94 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 124 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 343 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 878 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2014 | 85 | 0.030 |
Why?
| | Warfare | 1 | 2014 | 63 | 0.030 |
Why?
| | Erythropoietin | 1 | 1994 | 90 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2013 | 35 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2120 | 0.030 |
Why?
| | Salicylates | 1 | 2013 | 30 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 1994 | 265 | 0.030 |
Why?
| | Urinalysis | 1 | 2013 | 73 | 0.030 |
Why?
| | Nursing Staff, Hospital | 1 | 1994 | 149 | 0.020 |
Why?
| | Iron | 1 | 1994 | 287 | 0.020 |
Why?
| | Hemoglobins | 1 | 1994 | 345 | 0.020 |
Why?
| | Long QT Syndrome | 1 | 2013 | 68 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2012 | 57 | 0.020 |
Why?
| | Therapeutic Irrigation | 1 | 2012 | 75 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 6 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 133 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 52 | 0.020 |
Why?
| | Agranulocytosis | 1 | 2011 | 30 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 950 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 20 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1167 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2012 | 136 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 128 | 0.020 |
Why?
| | Toothache | 1 | 2010 | 6 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 334 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2015 | 611 | 0.020 |
Why?
| | Models, Theoretical | 1 | 1994 | 553 | 0.020 |
Why?
| | Immunoassay | 1 | 2011 | 102 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 39 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2012 | 223 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 201 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2010 | 114 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 1994 | 739 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 379 | 0.020 |
Why?
| | Intestines | 1 | 2012 | 347 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 643 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 560 | 0.020 |
Why?
| | Safety | 1 | 2010 | 333 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 388 | 0.020 |
Why?
| | Triage | 1 | 2010 | 214 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 588 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 991 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 503 | 0.020 |
Why?
| | Clinical Competence | 1 | 2014 | 1029 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 597 | 0.020 |
Why?
| | Bilirubin | 1 | 2007 | 92 | 0.020 |
Why?
| | Pulse | 1 | 2006 | 27 | 0.020 |
Why?
| | Metabolomics | 1 | 2012 | 599 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1839 | 0.020 |
Why?
| | Blastomycosis | 1 | 2006 | 9 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 90 | 0.020 |
Why?
| | Amyloidosis | 1 | 2006 | 39 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 66 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2006 | 138 | 0.020 |
Why?
| | Electric Countershock | 1 | 2006 | 107 | 0.020 |
Why?
| | European Union | 1 | 2005 | 10 | 0.020 |
Why?
| | Fever | 1 | 2007 | 303 | 0.020 |
Why?
| | Disaster Planning | 1 | 2006 | 84 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2007 | 5741 | 0.020 |
Why?
| | Emergencies | 1 | 2006 | 164 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2006 | 675 | 0.010 |
Why?
| | United States Food and Drug Administration | 1 | 2005 | 205 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 856 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2006 | 152 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 172 | 0.010 |
Why?
| | Swine | 1 | 2006 | 744 | 0.010 |
Why?
| | Brain Injuries | 1 | 2009 | 468 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 114 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 2004 | 56 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3084 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1067 | 0.010 |
Why?
| | Papillary Muscles | 1 | 2001 | 15 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2001 | 196 | 0.010 |
Why?
| | Miosis | 1 | 1999 | 3 | 0.010 |
Why?
| | Pupil | 1 | 1999 | 13 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1753 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1099 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1727 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1638 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2321 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5285 | 0.010 |
Why?
| | Neoplasms | 1 | 2006 | 2467 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|